Healthcare >> Sector Roundtables >> January 10, 2005


DAVID DEAN, Healthcare and Biotechnology Analyst with Sprott Securities Inc., has been in the investment business since 2000 and with Sprott since 2002. He was previously with Yorkton Securities, Desjardins Securities, and the Ottawa Heart Institute and the National Research Council. He has an MSc (Physiology) from the University of Ottawa, 1995 and an MBA (Finance) from Queen's University, 2000. Profile
BARBARA A. JOHNSTON has been a Life Sciences Analyst with Haywood Securities Inc. in Vancouver, British Columbia, since 2000. In this position, Dr. Johnston assesses both private and public biotechnology and healthcare companies for investment opportunities. She also researches and evaluates value and growth prospects for private biotech and medical device companies. Prior to joining Haywood Securities, Dr. Johnston served for a year as the Associate Director of Professional Services at Charles River Laboratories in Wilmington, Massachusetts. In this role, she professionally oversaw the world's largest research animal diagnostic laboratory. Before that, Dr. Johnston spent 12 years as the Vavarium Director of Animal Health Resources at the Fred Hutchinson Cancer Research Center in Seattle. Dr. Johnston received her board certification from the American College of Laboratory Animal Science in 1994 after performing her residency in Laboratory Animal Medicine at the University of Washington. She received her Doctorate in Veterinary Medicine from Washington State University in 1985, after completing her bachelor's degree in Biology and Fisheries from the University of Washington in 1981. Profile
TWST: Barbara, can you give us a quick overview of Haywood Securities?

Ms. Johnston: Our firm has offices in Vancouver, Toronto, and Calgary.

Vancouver is the head office. We're a very